- Home
- AEC vs NMRA Comparison
AEC vs NMRA Comparison
Compare AEC & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AEC | NMRA |
|---|---|---|
| Founded | 1989 | 2019 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.0M | 87.4M |
| IPO Year | 2011 | 2023 |
Fundamental Metrics
Financial Performance| Metric | AEC | NMRA |
|---|---|---|
| Price | $3.09 | $0.39 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $6.14 |
| AVG Volume (30 Days) | 38.8K | ★ 1.8M |
| Earning Date | 05-01-2015 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.70 | $0.32 |
| 52 Week High | $10.24 | $3.65 |
Technical Indicators
Market Signals| Indicator | AEC | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 45.59 | 31.04 |
| Support Level | $2.80 | $0.32 |
| Resistance Level | $5.11 | $1.72 |
| Average True Range (ATR) | 0.19 | 0.06 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 71.67 | 37.00 |
Price Performance
Historical ComparisonAbout AEC Anfield Energy Inc.
Anfield Energy Inc is a mineral exploration and development company. This company focuses on uranium and vanadium development and near-term production. The exploration project of the company includes Shootaring Canyon Mill and Velvet-Wood and Slick Rock Uranium Project from Uranium One and The West Slope Project located in Montrose and San Miguel Counties in southwestern Colorado. The company's geographical segments are Canada and the United States.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.